vutrisiran

Alnylam changes to heart drug trial spark doubts, sinking shares
BioPharma Dive
Thu, 02/15/24 - 07:13 pm
Alnylam
clinical trials
vutrisiran
ATTR
Alnylam scraps trial in rare eye disorder, blaming drug price reforms
Pharmaphorum
Fri, 10/28/22 - 10:25 am
Alnylam
RNAi
vutrisiran
Stargardt disease
Inflation Reduction Act
drug pricing
Alnylam's potential fourth RNAi approval delayed three months, but impact likely to be 'modest'
Endpoints
Mon, 04/4/22 - 11:08 pm
Alnylam
RNAi
FDA
vutrisiran
The biggest launches of 2022: a reboot
EP Vantage
Mon, 02/14/22 - 10:48 am
drug launches
Eli Lilly
tirzepatide
Alnylam
vutrisiran
Roche
Vabysmo
JNJ
Carvykti
Mirati Therapeutics
adagrasib
Bristol Myers Squibb
mavacamten
deucravacitinib
SFNP 2022 – Alnylam takes heart from its Onpattro follow-on
EP Vantage
Tue, 01/25/22 - 10:41 am
Alnylam
vutrisiran
Onpattro
hereditary ATTR amyloidosis
Alnylam, awaiting key study data, builds case for its next rare disease drug
BioPharma Dive
Sat, 01/22/22 - 02:12 pm
Alnylam
ATTR
vutrisiran
7 drugs likely to hit $1B in annual revenue in the next 5 years
Beckers Hospital Review
Thu, 01/13/22 - 07:31 am
FDA
adagrasib
donanemab
faricimab
lecanemab
tezepelumab
tirzepatide
vutrisiran
Eli Lilly
Mirati Therapeutics
Roche
Chugai
Eisai
Biogen
AstraZeneca
Amgen
Alnylam
AAN 2021 – Helios backs Alnylam’s sunny forecasts
EP Vantage
Wed, 04/21/21 - 10:28 am
Alnylam
AAN
vutrisiran
Onpattro
hATTR amyloidosis
Biotech’s important clinical data readouts
EP Vantage
Fri, 03/26/21 - 10:35 am
biotech
Scholar Rock
apitegromab
spinal muscular atrophy
Alnylam
vutrisiran
Dicerna
nedosiran
Primary Hyperoxaluria
FDA
Alnylam's next-gen ATTR amyloidosis drug hits goals in phase 3, teeing up approval filing
Fierce Biotech
Thu, 01/7/21 - 11:33 am
clinical trials
Alnylam
ATTR amyloidosis
vutrisiran
Alnylam's vutrisiran gets fast-track treatment at the FDA
Fierce Biotech
Tue, 04/14/20 - 09:44 am
Alnylam
RNAi
FDA
hATTR
vutrisiran
fast track